What is the share price of Rubicon Research Ltd (RUBICON) today?
The share price of RUBICON as on 2nd March 2026 is ₹773.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Rubicon Research Ltd (RUBICON) share?
The past returns of Rubicon Research Ltd (RUBICON) share are- Past 1 week: -1.26%
- Past 1 month: 14.94%
- Past 3 months: 21.33%
- Past 6 months: 23.11%
- Past 1 year: 23.11%
- Past 3 years: N/A%
- Past 5 years: 23.11%
What are the peers or stocks similar to Rubicon Research Ltd (RUBICON)?
The peers or stocks similar to Rubicon Research Ltd (RUBICON) include:What is the dividend yield % of Rubicon Research Ltd (RUBICON) share?
The current dividend yield of Rubicon Research Ltd (RUBICON) is 0.00.What is the market cap of Rubicon Research Ltd (RUBICON) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Rubicon Research Ltd (RUBICON) is ₹12741.79 Cr as of 2nd March 2026.What is the 52 week high and low of Rubicon Research Ltd (RUBICON) share?
The 52-week high of Rubicon Research Ltd (RUBICON) is ₹822 and the 52-week low is ₹570.75.What is the PE and PB ratio of Rubicon Research Ltd (RUBICON) stock?
The P/E (price-to-earnings) ratio of Rubicon Research Ltd (RUBICON) is 94.83. The P/B (price-to-book) ratio is 23.55.Which sector does Rubicon Research Ltd (RUBICON) belong to?
Rubicon Research Ltd (RUBICON) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Rubicon Research Ltd (RUBICON) shares?
You can directly buy Rubicon Research Ltd (RUBICON) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Rubicon Research Ltd
RUBICON Share Price
NSE₹773.400.89% (-6.95)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
RUBICON Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
RUBICON Performance & Key Metrics
RUBICON Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 61.78 | 23.55 | 0.00% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.67 | 5.79 | 0.58% |
100%
Analysts have suggested that investors can buy this stock
from 2 analysts
Price Upside
Earnings Growth
Rev. Growth
RUBICON Company Profile
Rubicon Research Ltd is a pharmaceutical formulations company focused on R&D of specialty and drug-device combination products for regulated markets, especially the US, offering multiple dosage forms and therapeutic areas including analgesics, CVS, CNS, gastrointestinal, and respiratory products.
SUNPHARMA
PE Ratio
38.47
38.47
1Y Return
10.56%
10.56%
Buy Reco %
94.29
94.29
TORNTPHARM
PE Ratio
77.37
77.37
1Y Return
47.65%
47.65%
Buy Reco %
81.48
81.48
CIPLA
PE Ratio
20.71
20.71
1Y Return
3.97%
3.97%
Buy Reco %
54.84
54.84
DRREDDY
PE Ratio
19.06
19.06
1Y Return
15.61%
15.61%
Buy Reco %
48.39
48.39
LUPIN
PE Ratio
32.19
32.19
1Y Return
18.34%
18.34%
Buy Reco %
72.22
72.22
RUBICON Sentiment Analysis
RUBICON Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
RUBICON Stock Summary · February 2026
In Q3 FY 2025-26, the company achieved a remarkable 52% year-over-year revenue growth, fueled by strong demand for its specialty products, which now significantly contribute to gross profit. While the increased reliance on outsourcing has pressured gross margins, management remains optimistic about stabilizing operating EBITDA margins between 22% and 23% as new manufacturing capabilities come online. Strategic investments in R&D, projected to exceed INR 500 crores, are expected to drive future revenue, particularly through innovative delivery systems and a diversified product portfolio. Additionally, the company is expanding its global footprint, including a new subsidiary in Saudi Arabia, positioning itself to leverage its innovative offerings in emerging markets. Overall, the positive market sentiment reflects confidence in the company’s growth trajectory and operational resilience.
RUBICON Stock Growth Drivers
RUBICON Stock Growth Drivers
7Strong Financial Performance
Rubicon Research Limited has reported impressive financial results, including a revenue from operations of INR
Successful R&D Investments
The company has emphasized the importance of R&D as a key driver of revenue growth,
RUBICON Stock Challenges
RUBICON Stock Challenges
2Working Capital Management Challenges
The company has reported a decrease in working capital days from 137 to 123, but
Regulatory Approval Uncertainties
There are significant concerns regarding the unpredictability of product approvals from regulatory authorities, particularly related
RUBICON Forecast
RUBICON Forecasts
Price
Revenue
Earnings
RUBICON Share Price Forecast
RUBICON Share Price Forecast
2026
Current
₹773.40
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹773.40
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
RUBICON Company Revenue Forecast
RUBICON Company Revenue Forecast
2025
Current
₹1.30
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹1.30
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
RUBICON Stock EPS (Earnings Per Share) Forecast
RUBICON Stock EPS (Earnings Per Share) Forecast
2025
Current
₹8.78
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹8.78
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
RUBICON
RUBICON
Income
Balance Sheet
Cash Flow
Quarterly Normal View
RUBICON Income Statement
RUBICON Income Statement
Quarterly Normal View
| Quarter | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 317.10 | 298.67 | 313.89 | 358.25 | 353.13 | 412.72 | 479.32 | |||||||
Operating & Other expenses | 256.49 | 234.35 | 243.50 | 285.67 | 273.38 | 317.72 | 367.40 | |||||||
EBITDA | 60.61 | 64.32 | 70.39 | 72.58 | 79.75 | 95.00 | 111.92 | |||||||
| Depreciation/Amortization | 9.36 | 8.15 | 9.42 | 9.66 | 9.57 | 11.87 | 11.55 | |||||||
| PBIT | 51.25 | 56.17 | 60.97 | 62.92 | 70.18 | 83.13 | 100.37 | |||||||
| Interest & Other Items | 10.09 | 7.02 | 7.82 | 11.85 | 10.62 | 11.42 | 9.77 | |||||||
| PBT | 41.16 | 49.15 | 53.15 | 51.07 | 59.56 | 71.71 | 90.60 | |||||||
| Taxes & Other Items | 15.60 | 14.68 | 15.08 | 14.81 | 16.25 | 17.85 | 17.79 | |||||||
| Net Income | 25.56 | 34.47 | 38.07 | 36.26 | 43.31 | 53.86 | 72.81 | |||||||
| EPS | 1.66 | 2.27 | 2.50 | 2.35 | 2.81 | 3.49 | 4.46 |
RUBICON Company Updates
FY 2026FY 2026
Investor Presentation
Feb 3PDF
Nov 13PDF
RUBICON Stock Peers
RUBICON Past Performance & Peer Comparison
RUBICON Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Rubicon Research Ltd | 94.83 | 23.55 | 0.00% |
| Sun Pharmaceutical Industries Ltd | 38.47 | 5.80 | 0.91% |
| Torrent Pharmaceuticals Ltd | 77.37 | 19.48 | 0.73% |
| Cipla Ltd | 20.71 | 3.49 | 1.18% |
RUBICON Stock Price Comparison
Compare RUBICON with any stock or ETFCompare RUBICON with any stock or ETF
RUBICON
RUBICON Holdings
RUBICON Shareholdings
RUBICON Promoter Holdings Trend
RUBICON Promoter Holdings Trend
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
RUBICON Institutional Holdings Trend
RUBICON Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 2.00%
Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has decreased by 1.38%
RUBICON Shareholding Pattern
RUBICON Shareholding Pattern
RUBICON Shareholding History
RUBICON Shareholding History
Foreign Institutions
Mutual Funds Invested in RUBICON
Mutual Funds Invested in RUBICON
No mutual funds holding trends are available
Top 5 Mutual Funds holding Rubicon Research Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.8669% | Percentage of the fund’s portfolio invested in the stock 0.40% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 70/71 (-4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2895% | Percentage of the fund’s portfolio invested in the stock 3.01% | Change in the portfolio weight of the stock over the last 3 months 0.32% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 5/57 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4351% | Percentage of the fund’s portfolio invested in the stock 2.32% | Change in the portfolio weight of the stock over the last 3 months 0.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 16/60 (0) |
Compare 3-month MF holding change on Screener
smallcases containing RUBICON stock
smallcases containing RUBICON stock
Looks like this stock is not in any smallcase yet.
RUBICON Events
RUBICON Events
RUBICON Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.00%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.02 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
RUBICON Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.00%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.02 every year
RUBICON Dividends
RUBICON Dividends
Hmm, looks like data is unavailable here. Please come back after some timeRUBICON Stock News & Opinions
RUBICON Stock News & Opinions
Articles & Videos
Spotlight
Rubicon Research surges after Q3 PAT jumps 91% YoY to Rs 73 cr
Profit before tax (PBT) jumped 70.42% YoY to Rs 90.58 crore in Q3 FY26. EBITDA stood at Rs 111.9 crore during the quarter, recording the growth of 59% compared with Rs 70.4 crore in Q3 FY25. EBITDA margin improved 23.5% in Q3 FY26 as against 22.3% in Q3 FY25. Revenue grew 52% year-on-year during the quarter, driven by broad-based performance. The top five products contributed 35% of total revenue in Q3 FY26, up from 30% in Q2 FY26 and 34% in Q1 FY26. Meanwhile, the top 10 products accounted for 53% of revenue, compared with 51% in Q2 FY26 and 56% in Q1 FY26. Reasearch & Development (R&D) expense climbed 100.38% to Rs 52.3 crore, compared with Rs 26.1 crore posted in corresponding quarter last year. R&D expenses were 11.0% of operating revenue in Q3 FY26. In dollar terms, the revenue stood at $53 million in Q3 FY26, up 46% YoY. Approximately 98% of the revenue was denominated in US dollars. Meanwhile, the company's board granted in-principle approval for the merger of KIA Health Tech, wholly owned subsidiary of the company, with Rubicon Research and their shareholders. Rubicon Research is a pharmaceutical formulations company focused on innovation-led research and development, with a growing portfolio of specialty products and drug'device combination offerings aimed at regulated markets.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
Rubicon Research consolidated net profit rises 91.23% in the December 2025 quarter
Net profit of Rubicon Research rose 91.23% to Rs 72.80 crore in the quarter ended December 2025 as against Rs 38.07 crore during the previous quarter ended December 2024. Sales rose 51.73% to Rs 475.53 crore in the quarter ended December 2025 as against Rs 313.40 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales475.53313.40 52 OPM %22.7422.30 - PBDT102.1462.57 63 PBT90.5953.15 70 NP72.8038.07 91 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Rubicon Research announces board meeting date
Rubicon Research will hold a meeting of the Board of Directors of the Company on 3 February 2026.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Rubicon Research incorporates WoS in Saudi Arabia
Rubicon Research announced the incorporation of a wholly owned subsidiary, AdvaGen S A Company in the Kingdom of Saudi Arabia with effect from 13 January 2026. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Rubicon Research consolidated net profit rises 56.18% in the September 2025 quarter
Net profit of Rubicon Research rose 56.18% to Rs 53.85 crore in the quarter ended September 2025 as against Rs 34.48 crore during the previous quarter ended September 2024. Sales rose 39.19% to Rs 412.02 crore in the quarter ended September 2025 as against Rs 296.01 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales412.02296.01 39 OPM %22.8820.83 - PBDT83.5857.30 46 PBT71.7149.15 46 NP53.8534.48 56 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Rubicon Research to convene board meeting
Rubicon Research will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 35.76%, vs industry avg of 9.88%
Over the last 5 years, market share increased from 0.11% to 0.31%
Over the last 5 years, net income has grown at a yearly rate of 22.14%, vs industry avg of 19.69%